Overexpression of lncRNA FEZF1-AS1 promotes progression of non-small cell lung cancer via the miR-130a-5p/CCND1 axis

doi:10.12122/j.issn.1673-4254.2024.05.05

Abstract

Abstract:

Objective To explore the molecular mechanism by which FEZF1-AS1 overexpression promotes progression of non-small cell lung cancer (NSCLC) via the miR-130a-5p/CCND1 axis. Methods TCGA database was used to analyze FEZF1-AS1 expression levels in NSCLC. FEZF1-AS1 expression was detected by qRT-PCR in clinical specimens of NSCLC tissues and NSCLC cell lines, and its correlation with clinical features of the patients were analyzed. The binding sites of FEZF1-AS1 with hsa-miR-130a-5p and those of hsa-miR-130a-5p with CCND1 were predicted. CCK8 assay, clone formation assay, scratch assay, and Transwell assay were employed to examine the effects of FEZF1-AS1 knockdown and hsa-miR-130a-5p inhibitor on proliferation, invasion, and migration abilities of lung cancer cell lines. Dual luciferase assay was used to verify the binding of FEZF1-AS1 with hsa-miR-130a-5p and the binding of hsa-miR-130a-5p with CCND1. Western blotting was performed to detect the changes in CCND1 protein expression level in H1299 and H358 cells following FEZF1-AS1 knockdown and treatment with hsa-miR-130a-5p inhibitor. Results FEZF1-AS1 was highly expressed in NSCLC tissues in close correlation with lymph node metastasis and also in H1299 and H358 cell lines (all P<0.05). FEZF1-AS1 knockdown obviously reduced proliferation, migration, and invasion abilities of NSCLC cells (P<0.05). Dual luciferase assay confirmed the binding of hsa-miR-130a-5p with FEZF1-AS1 and CCND1 (P<0.05), and hsa-miR-130a-5p inhibitor significantly inhibited proliferation, migration, and invasion of NSCLC cells (P<0.05). FEZF1-AS1 knockdown significantly reduced CCND1 protein expression in NSCLC cells, and this effect was strongly inhibited by treatment with hsa-miR-130a-5p inhibitor (P<0.05). Conclusion FEZF1-AS1 is highly expressed in NSCLC tissue in close correlation with lymph node metastasis to promote cancer progression through the miR-130a-5p/CCND1 axis.

Key words: non-small cell lung cancer, lncRNA, FEZF1-AS1, miR-130a-5p, CCND1

Feifan LI, Junxin XIANG, Jiahui LIU, Xiaojing WANG, Hao JIANG. Overexpression of lncRNA FEZF1-AS1 promotes progression of non-small cell lung cancer via the miR-130a-5p/CCND1 axis[J]. Journal of Southern Medical University, 2024, 44(5): 841-850.

Figures/Tables 7

Fig.1 Expression of FEZF1-AS1 in non-small cell lung cancer (NSCLC) tissues and cell lines. A: Expression of FEZF1-AS1 in pan-cancer in TCGA database. B: Expression of FEZF1-AS1 in unpaired (left) and paired (right) human lung cancer tissues in the TCGA database. C: Expression of FEZF1-AS1 in human NSCLC tissue. D: Expression of FEZF1-AS1 in human lung cancer cell lines. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.

Tab.1 Relationship between FEZF1-AS1 expression in NSCLC and clinical features of the patients （n）

Clinical features	Expression of FEZF1-AS1		χ²	P
Clinical features	High expression group (n=16)	Low expression group (n=17)	χ²	P
Age (year)
<60	5	7	0.351	0.554
≥60	11	10	0.351	0.554
Gender
Male	2	9	6.066	0.014
Female	14	8	6.066	0.014
Smoking history
Yes	1	6	4.160	0.041
No	15	11	4.160	0.041
Tumor size (cm)
≤5	15	16	0.002	0.965
>5	1	1	0.002	0.965
Lymph node metastasis
Yes	13	6	7.127	0.008
No	3	11	7.127	0.008
TNM stage
Ⅰ-Ⅱ	13	14	0.000	1.000
Ⅲ-Ⅳ	3	3	0.000	1.000

Fig.2 Effect of FEZF1-AS1 on proliferation, migration, and invasion of H1299 and H358 cells. A: Fluorescence microscopy of the cells transfected with si-FEZF1-AS1. B: Knockdown efficiency of si-FEZF1-AS1 in H1299 and H358 cells. C: CCK-8 assay of proliferation of H1299 and H358 cells after transfection with si-FEZF1-AS1 and si-NC. D: Formation of H1299 and H358 clones after transfection. E: Healing of H1299 and H358 cell scratches after transfection. F: Transwell migration assay of H1299 and H358 cells after transfection. G: Transwell invasion assay of H1299 and H358 cells after transfection. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.

Fig.3 Binding of FEZF1-AS1 to hsa-miR-130a-5p. A: Prediction of binding sites between FEZF1-AS1 and hsa-miR-130a-5p. B: Dual luciferase reporter assay of the binding between FEZF1-AS1 and hsa-miR-130a-5p. ***P<0.001.

Fig.4 Effect of hsa-miR-130a-5p expression level on proliferation, migration, and invasion of H1299 and H358 cells. A: Expression of hsa-miR-130a-5p in the cells after transfection with si-FEZF1-AS1+NC inhibitor and with si-FEZF1-AS1+hsa-miR-130a-5p inhibitor. B: Effect of si-FEZF1-AS1+NC inhibitor and si-FEZF1-AS1+hsa miR-130a-5p inhibitor on cell proliferation. C: Effect of si-FEZF1-AS1+NC inhibitor and si-FEZF1-AS1+hsa miR-130a-5p inhibitor on cell migration. D: Effect of si-FEZF1-AS1+NC inhibitor and si-FEZF1-AS1+hsa-miR-130a-5p inhibitor on cell invasion. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.

Fig.5 Binding status of hsa-miR-130a-5p with CCND1. A: Volcano map of differential gene expression between si-FEZF1-AS1 (group 2) and si-NC groups (group 1) by transcriptome sequencing. B: Database prediction of downstream target proteins and transcriptome sequencing results shown in Venn diagram. C: Knockdown of FEZF1-AS1 and expression of CCND1 in H1299 cells. D: Knockdown of FEZF1-AS1 and expression of CCND1 in H358 cells. E: Prediction of binding sites between hsa-miR-130a-5p and CCND1. F: Dual luciferase reporter assay of binding between hsa-miR-130a-5p and CCND1. ***P<0.001, ****P<0.0001.

Fig.6 FEZF1-AS1/hsa miR-130a-5p regulates CCND1 expression through ceRNA mechanism. A: Expression levels of CCND1 in H1299 cells transfected with si-FEZF1-AS1+NC inhibitor and si-FEZF1-AS1+hsa-miR-130a-5p inhibitor. B: Expression levels of CCND1 in H358 cell transfected with si-FEZF1-AS1+NC inhibitor and si-FEZF1-AS1+hsa-miR-130a-5p inhibitor. C: Protein expression of CCND1 in H1299 cells transfected with si-NC, si-FEZF1-AS1, si-FEZF1-AS1+NC inhibitor and si-FEZF1-AS1+hsa-miR-130a-5p inhibitor. D: Protein expression of CCND1 in H358 cells transfected with si-NC, si-FEZF1-AS1, si-FEZF1-AS1+NC inhibitor and si-FEZF1-AS1+hsa-miR-130a-5p inhibitor. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.

References 27

1	Brody H. Lung cancer[J]. Nature, 2020, 587(7834): S7. DOI: 10.1038/d41586-020-03152-0
2	Cheung CHY, Juan HF. Quantitative proteomics in lung cancer[J]. J Biomed Sci, 2017, 24(1): 37. DOI: 10.1186/s12929-017-0343-y
3	Li FB, Gu FM, Li Q, et al. ROR1-AS1 knockdown inhibits growth and invasion and promotes apoptosis in NSCLC cells by suppression of the PI3K/Akt/mTOR pathway[J]. J Biochem Mol Toxicol, 2021, 35(5): e22726. DOI: 10.1002/jbt.22726
4	Fang YW, Fullwood MJ. Roles, functions, and mechanisms of long non-coding RNAs in cancer[J]. Genomics Proteomics Bioinformatics, 2016, 14(1): 42-54. DOI: 10.1016/j.gpb.2015.09.006
5	Barrett T, Troup DB, Wilhite SE, et al. NCBI GEO: archive for functional genomics data sets: 10 years on[J]. Nucleic Acids Res, 2011, 39(Database issue): D1005-10. DOI: 10.1093/nar/gkq1184
6	Temraz S, Mukherji D, Alameddine R, et al. Methods of overcoming treatment resistance in colorectal cancer[J]. Crit Rev Oncol Hematol, 2014, 89(2): 217-30. DOI: 10.1016/j.critrevonc.2013.08.015
7	Zhang MH, Yang Y, Zhao Y, et al. LncRNA DQ786243 expression as a biomarker for assessing prognosis in patients with gastric cancer[J]. Eur Rev Med Pharmacol Sci, 2018, 22(8): 2304-9.
8	Zhang Q, Chen BY, Liu P, et al. XIST promotes gastric cancer (GC) progression through TGF‑β1 via targeting miR-185[J]. J Cell Biochem, 2018, 119(3): 2787-96. DOI: 10.1002/jcb.26447
9	Yu WJ, Sun ZN, Yang L, et al. lncRNA PTAR promotes NSCLC cell proliferation, migration and invasion by sponging microRNA-101[J]. Mol Med Rep, 2019, 20(5): 4168-74.
10	Chen S, Zhou L, Ran RZ, et al. Circ_0016760 accelerates non-small-cell lung cancer progression through miR-646/AKT3 signaling in vivo and in vitro [J]. Thorac Cancer, 2021, 12(23): 3223-35. DOI: 10.1111/1759-7714.14191
11	Bian ZH, Zhang JW, Li M, et al. LncRNA-FEZF1-AS1 promotes tumor proliferation and metastasis in colorectal cancer by regulating PKM2 signaling[J]. Clin Cancer Res, 2018, 24(19): 4808-19. DOI: 10.1158/1078-0432.ccr-17-2967
12	Liang M, Li YK, Dai TT, et al. lncRNA FEZF1-AS1 regulates biological behaviors of cervical cancer by targeting miRNA-1254[J]. Food Sci Nutr, 2021, 9(9): 4722-37. DOI: 10.1002/fsn3.2315
13	周丽亚. FEZF1-AS1和AKT3在中晚期肺腺癌中的表达及与EGFR-TKIs疗效关系的研究[D]. 蚌埠: 蚌埠医学院, 2022: 1-2.
14	Shi CL, Sun L, Song YS. FEZF1-AS1: a novel vital oncogenic lncRNA in multiple human malignancies[J]. Biosci Rep, 2019, 39(6): BSR20191202. DOI: 10.1042/bsr20191202
15	Li M, Wei L, Liu PY, et al. Lnc-ATG9B-4 aggravates progress of hepatocellular carcinoma through cell proliferation and migration by upregulating CDK5[J]. Exp Biol Med, 2021, 246(2): 177-86. DOI: 10.1177/1535370220963197
16	Luo HL, Luo T, Liu JJ, et al. Macrophage polarization-associated lnc-Ma301 interacts with caprin-1 to inhibit hepatocellular carcinoma metastasis through the Akt/Erk1 pathway[J]. Cancer Cell Int, 2021, 21(1): 422. DOI: 10.1186/s12935-021-02133-1
17	Wang J, Tan LR, Yu XT, et al. lncRNA ZNRD1-AS1 promotes malignant lung cell proliferation, migration, and angiogenesis via the miR-942/TNS1 axis and is positively regulated by the m⁶A reader YTHDC2[J]. Mol Cancer, 2022, 21(1): 229. DOI: 10.1186/s12943-022-01705-7
18	Liu WW, Li Y, Zhang Y, et al. Circulatinglong non-coding RNA FEZF1-AS1 and AFAP1-AS1 serve as potential diagnostic biomarkers for gastric cancer[J]. Pathol Res Pract, 2020, 216(1): 152757. DOI: 10.1016/j.prp.2019.152757
19	Hui YJ, Yang Y, Li DP, et al. LncRNA FEZF1-AS1 modulates cancer stem cell properties of human gastric cancer through miR-363-3p/HMGA2[J]. Cell Transplant, 2020, 29: 963689720925059. DOI: 10.1177/0963689720925059
20	Zhu DW, Huang J, Liu N, et al. PSMC2/CCND1 axis promotes development of ovarian cancer through regulating cell growth, apoptosis and migration[J]. Cell Death Dis, 2021, 12(8): 730. DOI: 10.1038/s41419-021-03981-5
21	Wei YJ, Chen W, Li ZH, et al. EIF3H stabilizes CCND1 to promotes intrahepatic cholangiocarcinoma progression via Wnt/β-catenin signaling[J]. FASEB J, 2022, 36(12): e22647. DOI: 10.1096/fj.202200913r
22	Sun T, Xu YJ, Jiang SY, et al. Suppression of the USP10/CCND1 axis induces glioblastoma cell apoptosis[J]. Acta Pharmacol Sin, 2021, 42(8): 1338-46. DOI: 10.1038/s41401-020-00551-x
23	Chen G, Hu M, Qu XS, et al. MicroRNA-584 directly targets CCND1 and inhibits cell proliferation and invasion in pancreatic cancer[J]. Mol Med Rep, 2019, 19(1): 719-26.
24	Hao XY, Jia QQ, Yuan JL, et al. MicroRNA-195 suppresses cell proliferation, migration and invasion in epithelial ovarian carcinoma via inhibition of the CDC42/CCND1 pathway[J]. Int J Mol Med, 2020, 46(5): 1862-72.
25	Liu DC, Liu HG, Gan JD, et al. LY2874455 and abemaciclib reverse FGF3/4/19/CCND1 amplification mediated gefitinib resistance in NSCLC[J]. Front Pharmacol, 2022, 13: 918317. DOI: 10.3389/fphar.2022.918317
26	Chen XD, Cheng P, Hu CH. LncRNA FEZF1-AS1 accelerates the migration and invasion of laryngeal squamous cell carcinoma cells through miR-4497 targeting GBX2[J]. Eur Arch Otorhinolaryngol, 2021, 278(5): 1523-35. DOI: 10.1007/s00405-021-06636-5
27	Xie RJ, Liu CB, Liu LF, et al. Long non-coding RNA FEZF1-AS1 promotes rectal cancer progression by competitively binding miR-632 with FAM83A[J]. Acta Biochim Biophys Sin, 2022, 54(4): 452-62. DOI: 10.3724/abbs.2022022

[1]	HAN Qiqi, YE Mengran, JIN Qili. Demethylzeylasteral inhibits proliferation, migration and invasion and promotes apoptosis of non-small cell lung cancer cells by inhibiting the AKT/CREB signaling pathway [J]. Journal of Southern Medical University, 2024, 44(2): 280-288.
[2]	KONG Xiang, ZHANG Teng, ZHANG Yan, GAO Linxi, WANG Wen, WANG Mengyan, WANG Guodong, LÜ Kun. Overexpression of lncRNA HEM2M alleviates liver injury in mice with non-alcoholic fatty liver disease [J]. Journal of Southern Medical University, 2024, 44(1): 1-8.
[3]	LUO Rui, TIAN Longhai, YANG Yongyao. Galangin inhibits oxidized low-density lipoprotein-induced angiogenic activity in human aortic endothelial cells by downregulating lncRNA H19 [J]. Journal of Southern Medical University, 2024, 44(1): 52-59.
[4]	XIN Chen, WANG Xiaoying, LI Xiang, CHEN Yu, WANG Xue, NING Jiaxi, YANG Shi, WANG Zhongqiong. LncRNA SOX2OT enhances 5-fluorouracil resistance of cholangiocarcinoma cells by promoting autophagy via up-regulating SIRT1 expression [J]. Journal of Southern Medical University, 2024, 44(1): 187-193.
[5]	ZHU Quan, HUANG Baisheng, WEI Leiyan, LUO Qizhi. Overexpression of LncRNA MEG3 promotes ferroptosis and enhances chemotherapy sensitivity of hepatocellular carcinoma cells to cisplatin [J]. Journal of Southern Medical University, 2024, 44(1): 17-24.
[6]	XIE Ziping, LIU Liwei, FANG Jincun, ZHONG Xingyi, LIN Junhao, CHEN Fengsheng. ARHGAP21 inhibits epithelial-mesenchymal transition by inactivating the WNT signaling pathway in non-small cell lung cancer [J]. Journal of Southern Medical University, 2023, 43(8): 1322-1332.
[7]	JIANG Yong, GE Wenting, ZHAO Ying, WU Yuge, HUO Yiming, PAN Lanting, CAO Shuang. LINC00926 promotes pyroptosis of hypoxia-induced human umbilical vein vascular endothelial cells by recruiting ELAVL1 [J]. Journal of Southern Medical University, 2023, 43(5): 807-814.
[8]	LIU Fang, PENG Lanzhu, XI Jingle. High expression of MYH9 inhibits apoptosis of non-small cell lung cancer cells through activating the AKT/c-Myc pathway [J]. Journal of Southern Medical University, 2023, 43(4): 527-536.
[9]	NIU Wenwen, RONG Xiangyu, ZHAO Qian, LIU Xuerou, XU Liansong, LI Shanshan, LI Xian. Wine-processed Chuanxiong Rhizoma enhances efficacy of aumolertinib against EGFR-mutant non-small cell lung cancer xenografts in nude mouse brain [J]. Journal of Southern Medical University, 2023, 43(3): 375-382.
[10]	ZHAO Qilin, WANG Nan, LI Yaji, WU Qingchen, WU Lanxiang. Lnc-TMEM132D-AS1 overexpression reduces sensitivity of non-small cell lung cancer cells to osimertinib [J]. Journal of Southern Medical University, 2023, 43(2): 242-250.
[11]	CAO Tianran, LIU Qingfang, PAN Meimin, ZHANG Xuehong. LncRNA SNHG8 inhibits miR-494-3p expression to alleviate cerebral ischemia-reperfusion injury in mice [J]. Journal of Southern Medical University, 2023, 43(12): 2015-2022.
[12]	KONG Dexian, SONG Liping, XIANG Yang. Construction of a prognostic nomogram combining PET/CT metabolic parameters and blood inflammatory markers for non-small cell lung cancer treated with first-line chemotherapy [J]. Journal of Southern Medical University, 2023, 43(12): 2139-2144.
[13]	WU Xiaofeng, ZHAN Riming, CHENG Dazhao, CHEN Li, WANG Tianyu, TANG Xudong. Exosomal FZD10 derived from non-small cell lung cancer cells promotes angiogenesis of human umbilical venous endothelial cells in vitro [J]. Journal of Southern Medical University, 2022, 42(9): 1351-1358.
[14]	WANG Jing, CHEN Xueyi, SUN Li, CHEN Xuemei, LI Hui, XIONG Binrui, WANG Haihua. Long noncoding RNA ZEB1-AS1 aggravates cerebral ischemia/reperfusion injury in rats through the HMGB1/TLR-4 signaling axis [J]. Journal of Southern Medical University, 2022, 42(8): 1134-1142.
[15]	LEI Kunyang, XIE Wenjie, SUN Ting, LIU Yifu, WANG Xu. MiR-744-5p inhibits the proliferation, invasion, and migration of clear-cell renal cell carcinoma cells by targeting CCND1 [J]. Journal of Southern Medical University, 2022, 42(5): 712-717.